|
[1]BRUIX J,GORES GJ,MAZZAFERRO V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.
|
|
[2]BRUIX J,HAN KH,GORES G,et al.Liver cancer:approaching a personalized care[J].J Hepatol,2015,62(1Suppl):s144-s156.
|
|
[3]YE SL.New advances in liver cancer research:a review of 2013[J].Chin J Hepatol,2014,22(1):2-4.(in Chinese)叶胜龙.2013年肝癌领域新进展[J].中华肝脏病杂志,2014,22(1):2-4.
|
|
[4]YE SL.Advances in research on hepatocellular carcinoma in 2014[J].Chin J Hepatol,2015,23(2):90-93.(in Chinese)叶胜龙.2014年肝细胞癌研究进展回顾[J].中华肝脏病杂志,2015,23(2):90-93.
|
|
[5]TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
|
|
[6]CHEN WQ,ZHENG RS,ZHANG SW,et al.Report of incidence and mortality in China cancer registries,2009[J].Chin J Cancer Res,2013,25(1):10-21.
|
|
[7]WEI KR,YU X,ZHENG RS,et al.Incidence and mortality of liver cancer in China,2010[J].Chin J Cancer,2014,33(8):388-394.
|
|
[8]HOU J,CAO XT.MicroRNAs in the management of hepatocellular carcinoma:new opportunities and challenges[J].Chin J Cancer Biother,2015,22(1):1-7.(in Chinese)侯晋,曹雪涛.MicroRNA与肝癌诊治:新的机遇和挑战[J].中国肿瘤生物治疗杂志,2015,22(1):1-7.
|
|
[9]OISHI N,YAMASHITA T,KANEKO.Molecular biology of liver cancer stem cells[J].Liver Cancer,2014,3(1):71-84.
|
|
[10]RAMAKRISHNA G,RASTOGI A,TREHANPATI N,et al.From cirrhosis to hepatocellular carcinoma:new molecular insights on inflammation and cellular senescence[J].Liver Cancer,2013,2(3-4):367-383.
|
|
[11] Chinese Society of Liver Cancer,Chinese Anti-Cancer Association,Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association,Chinese Society of Pathology,Chinese AntiCancer Association,et al.Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer(2015 edition)[J].J Clin Hepatol,2015,31(6):833-839.(in Chinese)中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志,2015,31(6):833-839..
|
|
[12]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.
|
|
[13]SONG P,GAO J,INAGAKI Y,et al.Biomarkers:evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China[J].Liver Cancer,2013,2(1):31-39.
|
|
[14]SHEN Q,FAN J,YANG XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large scale,multicentre study[J].Lancet Oncol,2012,13(8):817-826.
|
|
[15]SAINI S,PRATT DS.Time to update radiological criteria for noninvasive diagnosis of hepatocellular carcinoma[J].Hepatol Int,2015,9(1):1-2.
|
|
[16]ICHUKAWA T,SANO K,MORISAKA H.Diagnosis of pathologically early HCC with EOB-MRI:experiences and current consensus[J].Liver Cancer,2014,3(2):97-107.
|
|
[17]TOYODA H,KUMADA T,TADA T,et al.Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC[J].Hepatol Int,2015,9(1):84-92.
|
|
[18]ZENG MS,YE HY,GUO L,et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter,open-label,phaseⅢstudy[J].Hepatobiliary Pancreat Dis Int,2013,12(6):607-616.
|
|
[19]SALVATORE V,BOLONDI L.Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions[J].Liver Cancer,2012,1(3-4):238-246.
|
|
[20]YAU T,TANG VYF,YAO TJ,et al.Development of Hong Kong Liver Cancer Staging System with treatment stratification for patients with hepatocellular carcinoma[J].Gastroenrerology,2014,146(7):1691-1700.
|
|
[21]XU Q,KOBAYASHI S,YE X,et al.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma:a meta-analysis of 16103 patients[J].Sci Rep,2014,4:7252.
|
|
[22]JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al.Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI Grade[J].J Clin Oncol,2015,33(6):550-558.
|
|
[23]AKAMATSU N,SUGAWARA Y,KOKUDO N.Living donor transplantation for patients with hepatocellular carcinoma[J].Liver Cancer,2014,3(2):108-118.
|
|
[24]LENCIONI R.Chemoembolization in patients with hepatocellular carcinoma[J].Liver Cancer,2012,1(1):41-50.
|
|
[25]FORNER A,GILABERT M,BRUIX J,et al.Treatment of intermediate-stage hepatocellular carcinoma[J].Nat Rev Clin Oncol,2014,11(9):525-535.
|
|
[26] RAOUL JL,GILABERT M,PIANA G.How to define transarterial chemoembolization failure or refractorness:a European perspective[J].Liver Cancer,2014,3(2):119-124.
|
|
[27]LIAPI E,GESCHWIND JF.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma[J].Liver Cancer,2012,1(3-4):201-205.
|
|
[28]SHEN YC,LIN ZZ,HSU CH,et al.Clinical trials in hepatocellular carcinoma:an update[J].Liver Cancer,2013,2(3-4):345-364.
|
|
[29]PARK JW,AMARAPURKAR D,CHAO Y,et al.Consensus recommendations and review by an international expert panel on interventions in hepatocellular carcinoma(EPOIHCC)[J].Liver Int,2013,33(3):327-337.
|
|
[30]KIM HY,PARK JW.Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma:past,present,and future[J].Liver Cancer,2014,3(1):9-17.
|
|
[31]JOHNSON PJ,QIN S,PARK JW,et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized phaseⅢBRISK-FL study[J].J Clin Oncol,2013,31(28):3517-3524.
|
|
[32]LLOVET JM,DECAENS T,RAOUL JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phaseⅢBRISK-PS study[J].J Clin Oncol,2013,31(28):3509-3516.
|
|
[33]CAINAP C,QIN S,HUANG WT,et al.Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phaseⅢtrial[J].J Clin Oncol,2015,33(2):172-179.
|
|
[34]ZHU AX,KUDO M,ASSENAT E,et al.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J].JAMA,2014,312(1):57-67.
|
|
[35]BRUIX J,TAK WY,GASBARRINI A,et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicentre,open-label,phase II safety study[J].Eur J Cancer,2013,49(16):3412-3419.
|
|
[36]QIN SK,BAI YX,LIM HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.
|
|
[37]CHOK KH,CHEUNG TT,CHAN SC,et al.Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J].World J Surg,2014,38(2):490-496.
|
|
[38]YAMAMOTO Y,IKOMA H,MORIMURA R,et al.Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].World J Gastroenterol,2015,21(1):246-253.
|
|
[39]XUE TC,XIE XY,ZHANG L,et al.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis:a meta-analysis[J].BMC Gastroenterol,2013,13:60.
|
|
[40]LEE DS,SEONG J.Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis[J].Liver Cancer,2014,3(1):18-30.
|
|
[41]JEONG SW,JANG JY,SHIM KY,et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(6):696-703.
|
|
[42]ZHU K,CHEN J,LAI L,et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J].Radiology,2014,272(1):284-293.
|
|
[43]PAN T,LI XS,XIE QK,et al.Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumor thrombus[J].Clin Oncol,2014,69(12):e553-561.
|
|
[44]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to treat hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol,2014,30(5):390-395.(in Chinese)肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志,2014,30(5):390-395.
|
|
[45]LAI CL,YUEN MF.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J].Hepatology,2013,57(1):399-408.
|
|
[46] YIN JH,LI N,HAN YF,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study[J].J Clin Oncol,2013,31(29):3647-3655.
|
|
[47]HUANG G,LAI EC,LAU WY,et al.Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J].Ann Surg,2013,257(3):490-505.
|
|
[48]DAN JQ,ZHANG YJ,HUANG JT,et al.Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma:a retrospective study[J].Eur J Surg Oncol,2013,39(8):865-872.
|
|
[49]BRIDGEWATER J,GALLE PR,KHAN SA,et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol,2014,60(6):1268-1289.
|
|
[50]WANG Y,LI J,XIA Y,et al.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J].J Clin Oncol,2013,31(9):1188-1195.
|
|
[51]YE SL.Attach importance to multidisciplinary combination therapy for liver cancer[J].Chin J Hepatol,2013,21(5):321-323.(in Chinese)叶胜龙.重视原发性肝癌的多学科综合治疗[J].中华肝脏病杂志,2013,21(5):321-323.
|
|
[52]CHOI C,CHOI GH,KIM TH,et al.Multimodality management for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma[J].Liver Cancer,2014,3:405-416.
|
|
[53]Society of Liver Cancer,Guangdong Provincial Anti-Cancer Association.Establishment of multi-disciplinary team for comprehensive treatment of liver cancer-consensus of experts in Guangdong,China(1)[J].J Clin Hepatol,2014,30(11):1112-1115.(in Chinese)广东省抗癌协会肝癌专业委员会.肝癌多学科综合治疗团队建立-广东专家共识(1)[J].临床肝胆病杂志,2014,30(11):1112-1115.
|
|
[54]Society of Liver Cancer,Guangdong Provincial Anti-Cancer Association.Strategy and method of multi-disciplinary team for comprehensive treatment of liver cancer-consensus of experts in Guangdong,China(2)[J].J Clin Hepatol,2014,30(11):1116-1119.(in Chinese)广东省抗癌协会肝癌专业委员会.肝癌多学科联合治疗策略与方法-广东专家共识(2)[J].临床肝胆病杂志,2014,30(11):1116-1119.
|
DownLoad: